Prestige Biologics (Korea) Investor Sentiment

334970 Stock  KRW 5,260  60.00  1.13%   
About 61% of Prestige Biologics' investor base is looking to short. The analysis of current outlook of investing in Prestige Biologics Co suggests that many traders are alarmed regarding Prestige Biologics' prospects. The current market sentiment, together with Prestige Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use Prestige Biologics stock news signals to limit their universe of possible portfolio assets.
  
over three months ago at news.google.com         
Prestige BioPharma secures EMAs positive opinion for Herceptin biosimilar - KBR
Google News at Macroaxis
over three months ago at news.google.com         
Retail investors who hold percent of Prestige Biologics Co., Ltd. gained 13, insiders profited as we...
Google News at Macroaxis
over three months ago at news.google.com         
Stock alert Gland Pharma, Gujarat Fluorochem, Ujjivan SFB, Prestige Estates, IREDA - Business Standa...
Google News at Macroaxis
over three months ago at news.google.com         
Stock alert Gland Pharma, Gujarat Fluorochem, Ujjivan SFB, Prestige Estates, IREDA - Business Standa...
Google News at Macroaxis
over six months ago at news.google.com         
Prestige Estates Projects shares fall 6 percent after CEO Venkata Narayana K steps down - Upstox
Google News at Macroaxis
over six months ago at news.google.com         
Prestige Estates shares jump nearly 7 percent on acquiring land in Ghaziabad for township project - ...
Google News at Macroaxis
over six months ago at news.google.com         
Retail investors invested in Prestige Biologics Co., Ltd. up 18 percent last week, insiders too were...
Google News at Macroaxis
over six months ago at news.google.com         
Global Bevacizumab Biosimilars Market Outlook 2024-2028 2033 Featuring Cipla, Reliance Lifesciences,...
Google News at Macroaxis
over a year ago at news.google.com         
Samsung, Celltrion set record targets as S. Korea banks on Bio Economy 2.0 - BioWorld Online
Google News at Macroaxis
over a year ago at news.google.com         
Prestige Biologics enters into MoU with Aurigene Pharmaceutical ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Reasons Why You Should Add AptarGroup to Your Portfolio - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
AptarGroup Gains From Solid Demand and Strategic Actions - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
BioBlast we 07 Jul 23 - Lexology
Google News at Macroaxis
over a year ago at news.google.com         
Public suggestions to be sought to enhance Brand Bengaluru Karnataka Deputy Chief Minister DK Shivak...
Google News at Macroaxis
over a year ago at news.google.com         
Special Shaperons exclusive technology to fuel global expansion - KBR
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Prestige Biologics that are available to investors today. That information is available publicly through Prestige media outlets and privately through word of mouth or via Prestige internal channels. However, regardless of the origin, that massive amount of Prestige data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Prestige Biologics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Prestige Biologics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Prestige Biologics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Prestige Biologics alpha.

Prestige Biologics Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Prestige Stock analysis

When running Prestige Biologics' price analysis, check to measure Prestige Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prestige Biologics is operating at the current time. Most of Prestige Biologics' value examination focuses on studying past and present price action to predict the probability of Prestige Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prestige Biologics' price. Additionally, you may evaluate how the addition of Prestige Biologics to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity